Chapter

Reconstructive Neurosurgery

Volume 101 of the series Acta Neurochirurgica Supplementum pp 89-92

Transgenic rodent models of Parkinson’s disease

  • B. K. HarveyAffiliated withIntramural Research Program, National Institute on Drug Abuse, National Institutes of Health
  • , Y. WangAffiliated withIntramural Research Program, National Institute on Drug Abuse, National Institutes of Health
  • , Barry J. HofferAffiliated withIntramural Research Program, National Institute on Drug Abuse, National Institutes of Health

Abstract

In the case of Parkinson’s disease (PD), classical animal models have utilized dopaminergic neurotoxins such as 6-hydroxydopamine (6OHDA) and 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP). More recently, human genetic linkage studies have identified several genes in familial forms of PD. Transgenic models have been made that explore the function of PD-linked genes (e.g. a-synuclein, DJ-1, LRRK2, Parkin, UCH-L1, PINK1). Recent evidence suggests mitochondrial dysfunction may play a major role in PD. Manipulation of mitochondrial respiratory genes (e.g. mitochondrial transcription factor A or TFAM) also elicits a PD phenotype in mice. Transgenic mice (MitoPark) were developed that have TFAM selectively knocked out in dopaminergic neurons. The nigral dopamine neurons of MitoPark mice show respiratory chain dysfunction, accompanied by the development of intraneuronal inclusions and eventual cell death. In early adulthood, the MitoPark mice show a slowly progressing loss of motor function that accompanies these cellular changes. The MitoPark mouse enables further study of the role of mitochondrial dysfunction in DA neurons as an important mechanism in the development of PD. Transgenic technology has allowed new insights into mechanisms of neurodegeneration for a number of neurological disorders. This paper will summarize recent studies on several transgenic models of PD.

Keywords

Parkinson’s disease DJ-1 PINK1 Parkin transgenic mitopark